Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on January 30, 2018, regarding events occurring on that date. The registrant is a Delaware corporation headquartered in Boston, MA, and has elected to be treated as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of a director:
- Robert Perez resigned as a director of Flex Pharma, Inc., effective January 31, 2018.
- Mr. Perez also resigned from the Compensation Committee of the Board of Directors.
- The resignation was voluntary, driven by Mr. Perez's desire to pursue other interests, and did not result from any disagreement with the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is limited to the disclosure of the director's resignation.
Key Facts for Investor Verification
- Verify the updated composition of the Board of Directors following Robert Perez's resignation.
- Confirm whether the Compensation Committee has appointed a replacement member.
- Note that the registrant is Flex Pharma, Inc., not Decoy Therapeutics Inc.